Catalog No.
Product Name
Application
Product Information
Citations
-
HMG-CoA reductase inhibitor
Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. -
HMG-CoA reductase inhibitor
Pitavastatin Calcium is a competitive inhibitor of the enzyme HMGCR (HMG-CoA reductase) results in a reduction in LDL cholesterol synthesis.- Weizhen Chen, .et al. , Biomaterials, 2021, 280:121260 PMID: 34823885
- Karis Tutuska, .et al. , Cell Death Dis, 2020, Apr; 11(4): 274 PMID: 32332697
- D Jarmuzek, .et al. , J Photochem Photobiol A Chem, 2019, November
- Marwan Ibrahim Abdullah, .et al. , Sci Rep, 2017, 7: 8090 PMID: 28808351
-
HMG-CoA reductase inhibitor
Rosuvastatin (Crestor) is a member of the drug class of statins, used to treat high cholesterol and related conditions, and to prevent cardiovascular disease. Rosuvastatin is a competitive inhibitor of the enzyme HMG-CoA reductase, having a mechanism of action similar to that of other statins. -
HMG-CoA reductase inhibitor
Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM. -
HMG-CoA reductase inhibitor
Rosuvastatin is a member of the drug class of statins, used to treat high cholesterol and related conditions, and to prevent cardiovascular disease. -
HMG-CoA Reductase inhibitor
Clinofibrate is a lipid clearing agent that appears to modify lipid metabolism, diminishing the steroid induced accumulation of lipids within osteocytes. It also can effectively reduce the plasma fibrinogen level.
-
HMG-CoA reductase inhibitor
Atorvastatin (Lipitor) is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of cholesterol. -
HMG-CoA reductase inhibitor
Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM, used for lowering cholesterol (hypolipidemic agent). -
HMG-CoA reductase inhibitor
Pravastatin sodium is a water-soluble, competitive inhibitor of 3-hydroxy-3-methyl coenzyme A (HMG-CoA) reductase. Potently blocks cholesterol synthesis in vivo (Ki~ 1 nM) and displays cardioprotective properties. -
HMG-CoA reductase inhibitor
Swertiamarin has shown potential as antiatherogenic agent by inhibiting HMG-CoA reductase activity in high cholesterol fed rats. -
HMG-CoA reductase inhibitor
Atorvastatin is an HMG-CoA reductase inhibitor (IC50 = 154 nM) that is effective in treating hypercholesterolemia and certain dyslipidemias.- Huang Y, .et al. , Mol Med Rep, 2016, Feb;13(2):1888-94 PMID: 26707502
-
HMG-CoA reductase inhibitor
Pitavastatin Lactone is an HMG-CoA reductase inhibitor. -
CoA reductase inhibitor
Atorvastatin, (+/-)- is a Hydroxymethylglutaryl-CoA reductase inhibitor. -
HMG-CoA reductase inhibitor
2-Hydroxy atorvastatin calcium salt is a hydroxy metabolite of Atorvastatin calcium salt. Atorvastatin is a potent HMG-CoA reductase inhibitor with an IC50 value of 8 nM. -
Cholesterol biosynthesis inhibitor
Monacolin J is an inhibitor of cholesterol biosynthesis, and inhibits the activity of HMG-CoA reductase. -
HMG-CoA reductase inhibitor
Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. -
HMG-CoA Reductase Inhibitor
Cerivastatin is a highly potent HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. This synthetic lipid-lowering agent effectively reduces low-density lipoprotein cholesterol levels. In addition to its lipid-modulating effects, Cerivastatin has exhibited inhibitory effects on the proliferation and invasiveness of MDA-MB-231 breast cancer cells, primarily through the inhibition of RhoA signaling, indicating potential applications in cancer research. -
HMG-CoA Reductase Inhibitor
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect. -
HMG-CoA Reductase Inhibitor
Pitavastatin is a potent HMG-CoA reductase inhibitor that effectively reduces cholesterol synthesis from acetic acid, demonstrating an IC50 of 5.8 nM in HepG2 cells. This compound functions as a potent inducer of low-density lipoprotein-cholesterol (LDL-C) receptors in hepatocytes. Additionally, Pitavastatin exhibits a broad range of biological activities, including anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective, and reno-protective effects, making it valuable for research in cardiovascular health and metabolic disorders. -
HMG-CoA Reductase (HMGCR) Inhibitor
Pravastatin is a competitive inhibitor of HMG-CoA reductase (HMGCR), playing a critical role in the regulation of cholesterol biosynthesis. With an IC50 value of 5.6 μM, it effectively reduces cholesterol levels and is commonly utilized in cardiovascular research. This compound is valuable for studies investigating lipid metabolism and the pharmacological modulation of cholesterol levels in various biological systems. -
HMG-CoA Reductase Inhibitor
Pitavastatin sodium is a potent inhibitor of hydroxymethylglutaryl-CoA (HMG-CoA) reductase, significantly reducing cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. This compound serves as an effective inducer of low-density lipoprotein-cholesterol (LDL-C) receptors in hepatocytes. In addition to its primary role in cholesterol regulation, pitavastatin sodium exhibits various biological activities, including anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective, and reno-protective effects, making it valuable for diverse research applications in lipid metabolism and disease. -
HMG-CoA Inhibitor
HMG499 is a potent and selective inhibitor of HMG-CoA reductase, exhibiting an IC50 of 0.41 μM. This compound effectively reduces serum cholesterol levels and mitigates the statin-induced accumulation of HMGCR, making it a valuable tool for research in lipid metabolism and atherosclerosis. HMG499 is relevant for studies investigating cholesterol regulation and cardiovascular disease pathways. -
HMG-CoA Reductase Inhibitor
Atorvastatin hemicalcium trihydrate is an orally active inhibitor of HMG-CoA reductase, primarily utilized in the management of dyslipidemia by effectively lowering blood lipid levels. Additionally, it demonstrates inhibitory effects on human smooth muscle cell proliferation and invasion, with IC50 values of 0.39 μM and 2.39 μM, respectively. This compound is valuable for research focused on atherosclerosis, cardiovascular diseases, and cell growth regulation. -
HMG-CoA Reductase Inhibitor
(3R,5S)-Fluvastatin sodium is a potent competitive inhibitor of HMG-CoA reductase, displaying an IC50 value of 8 nM. This compound is effective in modulating lipid levels and exhibits protective effects on vascular smooth muscle cells by activating the Nrf2-dependent antioxidant pathway, mitigating oxidative stress. It is widely utilized in cardiovascular research and studies focusing on cholesterol metabolism and oxidative stress responses. -
HMG-CoA Reductase Inhibitor
(3R,5R)-Rosuvastatin is a competitive inhibitor of HMG-CoA reductase, exhibiting an IC50 value of 11 nM. This compound is known for its ability to significantly reduce levels of low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein. Additionally, (3R,5R)-Rosuvastatin has been shown to inhibit human ether-a-go-go related gene (hERG) currents with an IC50 of 195 nM, impacting hERG protein expression and its interactions with heat shock protein 70 (Hsp70). Its pharmacological profile makes it valuable for research related to cholesterol management and cardiovascular health. -
HMG-CoA Reductase Inhibitor
(3S,5R)-Rosuvastatin is a competitive inhibitor of HMG-CoA reductase, exhibiting an IC50 of 11 nM. This agent plays a significant role in reducing low-density lipoprotein (LDL) cholesterol and triglyceride levels while decreasing C-reactive protein levels. Additionally, (3S,5R)-Rosuvastatin inhibits the hERG channel with an IC50 of 195 nM and modulates the expression of the hERG protein through the disruption of its interaction with heat shock protein 70 (Hsp70). This compound is valuable in cardiovascular research and studies focused on cholesterol metabolism. -
HMG-CoA Reductase Inhibitor
(3S,5R)-Fluvastatin-d6 is a deuterium-labeled derivative of the HMG-CoA reductase inhibitor, Fluvastatin. As a competitive inhibitor with an IC50 of 8 nM, it effectively regulates cholesterol biosynthesis. This compound has been shown to protect vascular smooth muscle cells from oxidative stress via the Nrf2-dependent antioxidant pathway, making it a valuable tool in cardiovascular research and studies focused on oxidative damage and cellular stress responses. -
HMG-CoA Reductase Inhibitor
Atorvastatin strontium is an HMG-CoA reductase inhibitor that effectively lowers cholesterol levels, impacting cardiovascular health. Its primary mechanism involves the inhibition of HMG-CoA reductase in liver tissue, which plays a crucial role in cholesterol synthesis. This compound is also utilized in research to address dyslipidemia and related metabolic disorders. -
HMG-CoA Reductase Inhibitor
Atorvastatin sodium is an orally active HMG-CoA reductase inhibitor that effectively reduces blood lipid levels. This compound demonstrates the ability to inhibit human smooth muscle cell proliferation and invasion, with IC50 values of 0.39 μM and 2.39 μM, respectively. Its capacity to modulate lipid metabolism makes it significant for research in cardiovascular diseases and metabolic disorders. -
HMG-CoA Synthase Inhibitor
Hymeglusin is a fungal β-lactone antibiotic that functions as a potent inhibitor of HMG-CoA synthase, exhibiting an IC50 of 0.12 μM. This compound covalently modifies the active cysteine residue at position 129 of the enzyme, thereby disrupting its activity. Hymeglusin is primarily utilized in research applications focused on lipid metabolism and studying the modulation of cholesterol biosynthesis pathways. -
α-Glucosidase/HMG-CoA reductase Dual Inhibitor
Ganomycin I is a dual inhibitor targeting α-Glucosidase and HMG-CoA reductase. It demonstrates significant anti-diabetic properties and inhibits HIV protease, contributing to its potential as an antiviral agent. Additionally, Ganomycin I shows effectiveness in preventing osteoclastogenesis, making it a valuable reagent for research in diabetes and bone metabolism. -
HMG-CoA Reductase (HMGCR) Inhibitor
SKF 104976 is a selective inhibitor of HMG-CoA reductase (HMGCR), demonstrating significant inhibitory activity in biochemical assays. It effectively reduces cholesterol synthesis in Hep G2 cells by inhibiting the incorporation of [14C]acetate at concentrations as low as 2 nM, leading to the accumulation of lanosterol and a substantial decrease in HMGR activity by 40-70%. Importantly, SKF 104976 does not influence low-density lipoprotein uptake or degradation, indicating a distinct regulatory mechanism for HMGR and low-density lipoprotein receptors. This compound serves as a valuable tool for studying cholesterol metabolism and the regulation of sterol synthesis pathways in cellular models. -
HMG-CoA Inhibitor
tert-Butyl Pitavastatin is a potent inhibitor of HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway. As a metabolite of Pitavastatin, it demonstrates significant biological activity in lowering lipid levels and managing hyperlipidemia. This compound is primarily utilized in pharmacological studies to explore cholesterol regulation and the therapeutic effects of statins in cardiovascular disease research. -
HMG-CoA reductase Inhibitor
Atorvastatin (lysine) is a potent inhibitor of HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway. This compound is primarily utilized in research focused on hypercholesterolemia and mixed hyperlipidemia, enabling studies on lipid regulation and cardiovascular health. Its ability to modulate cholesterol levels makes it valuable for investigating therapeutic approaches for dyslipidemia-related conditions. -
HMG-CoA Reductase Inhibitor
BMS-180431 is a potent inhibitor of HMG-CoA reductase, with an IC50 value of 43 nM. This compound effectively reduces cholesterol biosynthesis, making it relevant for research in lipid metabolism and cardiovascular disease. It is applicable in studies exploring hyperlipidemia, atherosclerosis, and related metabolic disorders. -
HMG-CoA Reductase (HMGCR) Inhibitor
Lovastatin hydroxy acid sodium is a potent inhibitor of HMG-CoA reductase (HMGCR), exhibiting a Ki of 0.6 nM. By effectively blocking the enzymatic action of HMGCR, this compound plays a critical role in cholesterol biosynthesis regulation. It is widely utilized in research to explore lipid metabolism, cardiovascular diseases, and therapeutic interventions for dyslipidemia. -
HMG-CoA Inhibitor
Pravastatin lactone is a potent HMG-CoA reductase inhibitor that functions as a metabolite of pravastatin. It effectively decreases blood cholesterol levels by inhibiting the synthesis of cholesterol in the liver. This compound is widely used in research related to lipid metabolism, cardiovascular diseases, and the development of cholesterol-lowering therapies. -
HMG-CoA Reductase (HMGCR) Inhibitor
β-Amyrin palmitate is an HMG-CoA reductase (HMGCR) inhibitor that plays a crucial role in lipid metabolism. This compound exhibits biological activity that can aid in the management of diabetes mellitus, making it a valuable reagent for research in metabolic disorders. Its ability to modulate cholesterol biosynthesis may also offer insights into cardiovascular health and related conditions. -
HMG-CoA Inhibitor
Bemfivastatin hemicalcium is an orally active inhibitor of HMG-CoA reductase (HMGCR), targeting cholesterol biosynthesis. This compound effectively promotes the liver's ability to extract lipids, leading to a significant reduction in blood lipid levels. Bemfivastatin hemicalcium is applicable in research on metabolic disorders, particularly in studying hypercholesterolemia and related conditions. -
HMG-CoA Inhibitor
Lovastatin acid is a potent competitive inhibitor of HMG-CoA reductase, with an inhibition constant (Ki) of 0.6 nM. As an active metabolite of Lovastatin, it effectively interferes with cholesterol synthesis by inhibiting the conversion of HMG-CoA to mevalonate. This compound is particularly valuable for research into hypercholesterolemia and related metabolic disorders. -
HMG-CoA Reductase Inhibitor
(3S,5S)-Pitavastatin calcium is a potent HMG-CoA reductase inhibitor effective in lowering cholesterol levels. It plays a significant role in the study of cardiovascular diseases by inhibiting lipid biosynthesis and improving lipid profiles. This compound is primarily utilized in research applications focused on atherogenesis and the investigation of statin therapy mechanisms. -
HMG-CoA Reductase Inhibitor
Rosuvastatin zinc salt is a zinc-complexed form of Rosuvastatin, an HMG-CoA reductase inhibitor. This compound effectively reduces cholesterol synthesis, making it valuable in atherosclerosis research. Its mechanism of action supports studies focusing on lipid regulation and cardiovascular disease prevention. -
HMG-CoA Reductase (HMGCR)
(3S,5R)-Fluvastatin potassium is an inhibitor of HMG-CoA reductase, a key enzyme in cholesterol biosynthesis. This compound exhibits antioxidative properties, influencing the oxidation of LDL in the presence of copper ions, akin to its 3R,5S enantiomer. Investigations have indicated that (3S,5R)-Fluvastatin potassium and its metabolites may possess anti-atherosclerotic effects through their antioxidative activities. It is commonly employed in research focused on cholesterol regulation and cardiovascular disease mitigation. -
HMG-CoA Reductase (HMGCR)
Ganoderic acid SZ is a potent inhibitor of HMG-CoA reductase (HMGCR), demonstrating superior activity compared to atorvastatin. This natural compound also significantly inhibits α-glucosidase derived from yeast, with low nanomolar IC50 values. Additionally, Ganoderic acid SZ exhibits cytotoxic effects against K562 leukemia cells, with IC50 values ranging from 10 to 20 μM. These properties make Ganoderic acid SZ a valuable tool for research in cholesterol metabolism and cancer studies. -
HMG-CoA Reductase Inhibitor
BMS-180431 sodium is a potent inhibitor of HMG-CoA reductase, with an IC50 value of 43 nM. This compound plays a pivotal role in cholesterol biosynthesis, making it valuable for research focused on lipid metabolism and related cardiovascular diseases. Its inhibitory effects on HMG-CoA reductase provide a useful tool for studying cholesterol-lowering interventions and the underlying mechanisms of dyslipidemia. -
HMG-CoA Reductase Inhibitor
L-645164 is a potent inhibitor of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase. This compound significantly reduces circulating serum cholesterol levels, demonstrating its efficacy in cholesterol management. Additionally, L-645164 shows potential for use in research related to central nervous system disorders, providing new avenues for investigation into therapeutic strategies. -
HMG-CoA Reductase Inhibitor
PF-3052334 is a potent, orally available inhibitor of HMG-CoA reductase, exhibiting an IC50 of 1.9 nM. This compound selectively inhibits cholesterol synthesis in hepatocytes with an IC50 of 0.9 nM, while displaying a significantly higher IC50 of 730 nM in muscle cells. PF-3052334 serves as a valuable tool for investigating hypercholesterolemia and related metabolic disorders. -
HMG-CoA Reductase Inhibitor
SQ-33600 is an HMG-CoA reductase inhibitor that exhibits cholesterol-lowering activity. It demonstrates significant selectivity, showing a much stronger inhibitory effect on rat hepatocytes (IC50: 93 nM) compared to human skin fibroblasts (IC50: 14200 nM). This compound is valuable for research on hypercholesterolemia and related metabolic disorders. -
HMG-CoA Reductase Inhibitor
Crilvastatin is a potent HMG-CoA reductase inhibitor that plays a critical role in cholesterol biosynthesis regulation. By inhibiting this key enzyme, Crilvastatin effectively lowers cholesterol levels, making it valuable for research in dyslipidemia and cardiovascular disease. This compound serves as a useful tool in studies aimed at understanding lipid metabolism and the therapeutic potential of statins in managing hyperlipidemic conditions.
